RxDoctor Payments Data

Rai Dilawar Shahjehan, MD

Internal Medicine · New Orleans, LANPI 1609305267

Payments from drug & device makers

$6,559in general payments, 2019–2025

Across 173 payments — averaging $37.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Boston Scientific$1K
  • Novartis$473
  • Pfizer$414
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$414
  • Abiomed$328
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$4968%
  • Food & beverage$5,64186%
  • Education$4226%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,559 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$6,051
Medicare patients
46
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan25$24,781
EliquisApixaban19$21,201
JardianceEmpagliflozin17$16,024
XareltoRivaroxaban12$7,680
Repatha SureclickEvolocumab14$7,408
Metoprolol Succinate31$447
Atorvastatin Calcium45$344
Midodrine Hcl18$286
Metoprolol Tartrate18$211
Furosemide37$163
Ezetimibe13$143
ClopidogrelClopidogrel Bisulfate17$134
Amlodipine Besylate23$102
Rosuvastatin Calcium22$98
Spironolactone17$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$473$24,78125 claims
PfizerEliquis$414$21,20119 claims
Boehringer IngelheimJardiance$74$16,02417 claims
Johnson & JohnsonXarelto$291$7,68012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →